A Phase 0 Imaging Trial of [²⁰³Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [²¹²Pb]Pb-VMT-α-NET.

求助中 20 由 Susan Buttlar 发布于 2026/2/13 8:44:50

DOI:10.2967/jnumed.125.270083
作者：Stephen A Graves,?David L Bushnell,?Michael K Schultz,?Sanchay Jain,?Kellie L Bodeker,?Yusuf Menda
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：Peptide receptor radionuclide therapy (PRRT) using α-particle emitters has potential to provide improved patient outcomes over those achieved with β-particle PRRT. A promising candidate radi

应助信息

等您来应助

上传文件

14小时前

Book学术机器人

2026/2/13 8:44:51 未找到该文献，机器人已退出，请等待人工下载

2026/2/13 8:44:51 Book学术AI机器人收到请求，开始寻找文献

2026/2/13 8:44:51 已向机器人发送请求

14小时前

Susan Buttlar 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Physical Society (APS)Theory of coupling in dispersive photonic systems

A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET.

A Phase 0 Imaging Trial of [²⁰³Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [²¹²Pb]Pb-VMT-α-NET.